More importantly, we developed a ROS‐responsive hydrogel for the localized delivery of the Nampt inhibitor FK866 and the Stat3 inhibitor C188‐9, demonstrating potent synergistic anti‐cancer effects. Here, STAT3 is linked to cancer.